查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1586431

特發性肺纖維化治療市場，規模，佔有率，趨勢，產業分析報告:各類藥物，各給藥途徑，各流通管道，各地區 - 市場預測，2025年～2034年

Idiopathic Pulmonary Fibrosis Treatment Market Size, Share, Trends, Industry Analysis Report: By Drug Class, Route of Administration, Distribution Channel, and Region - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 118 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris Market Research 的一項新研究，全球特發性肺纖維化治療市場預計到 2034 年將達到 78.1 億美元。該研究報告對當前市場動態提供了詳細的見解，並對未來市場成長進行了分析。

特發性肺纖維化治療市場受到生活方式改變的顯著推動，例如吸菸和久坐行為的增加，以及接觸污染物的增加。這些因素導致包括特發性肺纖維化 (IPF) 在內的肺部疾病盛行率不斷上升，因為惡劣的空氣品質和不健康的生活習慣會影響呼吸系統健康。此外，人們對特發性肺纖維化及其風險因素的認識不斷提高，促進了早期診斷和治療。隨著生活方式的不斷變化，未來幾年對有效的特發性肺纖維化藥物的需求預計將上升。

特發性肺纖維化盛行率的上升正在推動特發性肺纖維化治療市場的成長。根據美國國立衛生研究院的數據，2021 年特發性肺纖維化的盛行率為每 10 萬人口 36 例。人們認識的提高和診斷方法的改進使得早期發現疾病變得更加容易，從而擴大了尋求治療的患者群體。因此，特發性肺纖維化盛行率的不斷上升加上診斷方法的進步，大大增加了對有效治療方案的需求，從而對市場成長產生了積極影響。

由於特發性肺纖維化是一種在老年人中特別普遍的疾病，預計在預測期內，全球老年人口的增加將顯著推動特發性肺纖維化治療市場的發展。在歐盟，超過 21.3% 的人口年齡在 65 歲或以上，對有效治療的需求日益增長。這種人口趨勢可能會導致特發性肺纖維化治療的需求大幅增加。

特發性肺纖維化治療市場報告重點

根據給藥途徑，預計口服劑型在預測期內將在全球市場上實現顯著的複合年增長率。這種成長歸功於多種優勢，包括易於使用和門診管理的可能性。

根據分銷管道，醫院藥房部門在 2024 年佔據了市場最大的收入佔有率，這歸因於住院率的提高以及需要高級治療的患者可以獲得專門的醫療服務。

由於其先進的醫療基礎設施，北美將在 2024 年佔據全球特發性肺纖維化治療市場的最大收入佔有率

由於製藥製造業的投資增加，印度特發性肺纖維化治療市場預計在預測期內將大幅成長。

全球主要的市場參與者包括F． Hoffmann-La Roche Ltd，Boehringer Ingelheim International GmbH，Bristol-Myers Squibb Company，Medicinova, Inc，Merck &Co, Inc，Galapagos NV，Novartis AG，Fibrogen, Inc.等。

目錄

第1章 簡介

第2章 摘要整理

第3章 調查手法

第4章 全球特發性肺纖維化治療市場洞察

  • 市場概述
  • 特發性肺纖維化治療市場動態
    • 促進因素和機會
      • 老齡人口增加推動市場成長
      • 診斷方法的進步正在擴大市場規模
    • 阻礙因素與課題
      • 有限的治療選擇
  • PESTEL分析
  • 特發性肺纖維化治療市場趨勢
  • 價值鏈分析
  • COVID-19影響分析

第5章 全球特發性肺纖維化治療市場:各類藥物

  • 主要調查結果
  • 簡介
  • 吡非尼酮
  • Nintedanib
  • 干擾素γ1b
  • 其他

第6章 全球特發性肺纖維化治療市場:各給藥途徑

  • 主要調查結果
  • 簡介
  • 口服
  • 注射可能
  • 其他

第7章 全球特發性肺纖維化治療市場:各流通管道

  • 主要調查結果
  • 簡介
  • 醫院藥局
  • 零售藥局
  • 其他

第8章 全球特發性肺纖維化治療市場:各地區

  • 主要調查結果
  • 簡介
    • 特發性肺纖維化治療市場評估:地區，2020年～2034年
  • 北美
    • 北美:各類藥物，2020年～2034年
    • 北美:各給藥途徑，2020年～2034年
    • 北美:各流通管道，2020年～2034年
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲:各類藥物，2020年～2034年
    • 歐洲:各給藥途徑，2020年～2034年
    • 歐洲:各流通管道，2020年～2034年
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 荷蘭
    • 俄羅斯
    • 其他歐洲
  • 亞太地區
    • 亞太地區:各類藥物，2020年～2034年
    • 亞太地區:各給藥途徑，2020年～2034年
    • 亞太地區:各流通管道，2020年～2034年
    • 中國
    • 印度
    • 馬來西亞
    • 日本
    • 印尼
    • 韓國
    • 澳洲
    • 其他亞太地區
  • 中東·非洲
    • 中東及非洲:各類藥物，2020年～2034年
    • 中東·非洲:各給藥途徑，2020年～2034年
    • 中東·非洲:各流通管道，2020年～2034年
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 南非
    • 其他中東和非洲
  • 南美
    • 南美:各類藥物，2020年～2034年
    • 南美:各給藥途徑，2020年～2034年
    • 南美:各流通管道，2020年～2034年
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他南美國家

第9章 競爭情形

  • 擴大和收購的分析
    • 擴大
    • 收購
  • 聯盟/合作/協定/公開

第10章 企業簡介

  • F. Hoffmann-La Roche Ltd
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Medicinova, Inc
  • Merck & Co., Inc.
  • Galapagos NV
  • Novartis AG
  • Fibrogen, Inc.
  • Avalyn Pharma Inc.
  • Promedior, Inc.
Product Code: PM5148

The global idiopathic pulmonary fibrosis treatment market size is expected to reach USD 7.81 billion by 2034, according to a new study by Polaris Market Research. The report "Idiopathic Pulmonary Fibrosis Treatment Market Size, Share, Trends, Industry Analysis Report: By Drug Class, Route of Administration, Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The idiopathic pulmonary fibrosis treatment market is significantly driven by changing lifestyle habits, such as rising smoking consumption and sedentary behavior, as well as increasing exposure to pollutants. These factors contribute to the rising incidence of lung diseases, including IPF, as poor air quality and unhealthy habits impact respiratory health. Additionally, the growing awareness of idiopathic pulmonary fibrosis and its risk factors encourages earlier diagnosis and treatment. As lifestyles continue to evolve, the demand for effective idiopathic pulmonary fibrosis therapies is expected to rise in the coming years.

The rising prevalence of idiopathic pulmonary fibrosis is driving the growth of the idiopathic pulmonary fibrosis treatment market. According to the National Institutes of Health, the prevalence of idiopathic pulmonary fibrosis was 36 cases per 100,000 people in 2021. The growing awareness and improving diagnostic methods facilitate earlier disease identification, expanding the patient population seeking treatment. Consequently, the combination of increasing idiopathic pulmonary fibrosis prevalence and advancements in diagnostics is significantly boosting demand for effective treatment options, positively impacting the market growth.

The growing number of geriatrics worldwide is expected to significantly drive the idiopathic pulmonary fibrosis treatment market during the forecast period, as older adults are particularly susceptible to the disease. In the European Union, over 21.3% of the population is aged 65 and older, highlighting the increasing demand for effective treatments. This demographic trend will likely lead to a substantial rise in the need for idiopathic pulmonary fibrosis therapies.

Idiopathic Pulmonary Fibrosis Treatment Market Report Highlights

Based on route of administration, the oral segment is anticipated to register a significant CAGR in the global market during the forecast period. This growth is attributed to its several advantages, including ease of use and potential of outpatient management.

By distribution channel, the hospital pharmacies segment accounted for the largest revenue share of the market in 2024 due to increasing hospitalization rates and the availability of specialized care for patients requiring advanced treatments.

In 2024, North America accounted for the largest revenue share of the global idiopathic pulmonary fibrosis treatment market due to its advanced medical infrastructure

The idiopathic pulmonary fibrosis treatment market in India is projected for significant growth during the forecast period due to the increased investments in its pharmaceutical manufacturing sector.

A few global key market players are F. Hoffmann-La Roche Ltd; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Medicinova, Inc; Merck & Co., Inc.; Galapagos NV; Novartis AG; and Fibrogen, Inc.

Polaris Market Research has segmented the idiopathic pulmonary fibrosis treatment market report on the basis of drug class, route of administration, distribution channel, and region:

By Drug Class Outlook (Revenue - USD Billion, 2020-2034)

  • Pirfenidone
  • Nintedanib
  • Interferon Gammato1b
  • Others
  • By Route of Administration (Revenue - USD Billion, 2020-2034)
  • Oral
  • Injectable
  • Others
  • By Distribution Channel (Revenue - USD Billion, 2020-2034)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Regional Outlook (Revenue - USD Billion, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of MEA

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Idiopathic Pulmonary Fibrosis Treatment Market Insights

  • 4.1. Idiopathic Pulmonary Fibrosis Treatment Market - Market Snapshot
  • 4.2. Idiopathic Pulmonary Fibrosis Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising Geriatric Population Are Driving Market Growth
      • 4.2.1.2. Advancement in Diagnostic Methods is Propelling Market Size
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Limited Treatment Options
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Idiopathic Pulmonary Fibrosis Treatment Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • 5.3. Pirfenidone
    • 5.3.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Pirfenidone, by Region, 2020-2034 (USD billion)
  • 5.4. Nintedanib
    • 5.4.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Nintedanib, by Region, 2020-2034 (USD billion)
  • 5.5. Interferon Gammato1b
    • 5.5.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Interferon Gammato1b, by Region, 2020-2034 (USD billion)
  • 5.6. Others
    • 5.6.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Others, by Region, 2020-2034 (USD billion)

6. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • 6.3. Oral
    • 6.3.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Oral, by Region, 2020-2034 (USD billion)
  • 6.4. Injectable
    • 6.4.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Injectable, by Region, 2020-2034 (USD billion)
  • 6.5. Others
    • 6.5.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Others, by Region, 2020-2034 (USD billion)

7. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • 7.3. Hospital Pharmacies
    • 7.3.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Hospital Pharmacies, by Region, 2020-2034 (USD billion)
  • 7.4. Retail Pharmacies
    • 7.4.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Retail Pharmacies, by Region, 2020-2034 (USD billion)
  • 7.5. Others
    • 7.5.1. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Others, by Region, 2020-2034 (USD billion)

8. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Idiopathic Pulmonary Fibrosis Treatment Market Assessment, By Geography, 2020-2034 (USD billion)
  • 8.3. Idiopathic Pulmonary Fibrosis Treatment Market - North America
    • 8.3.1. North America: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
    • 8.3.2. North America: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
    • 8.3.3. North America: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.3.4. Idiopathic Pulmonary Fibrosis Treatment Market - U.S.
      • 8.3.4.1. U.S.: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.3.4.2. U.S.: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.3.4.3. U.S.: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.3.5. Idiopathic Pulmonary Fibrosis Treatment Market - Canada
      • 8.3.5.1. Canada: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.3.5.2. Canada: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.3.5.3. Canada: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • 8.4. Idiopathic Pulmonary Fibrosis Treatment Market - Europe
    • 8.4.1. Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
    • 8.4.2. Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
    • 8.4.3. Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.4.4. Idiopathic Pulmonary Fibrosis Treatment Market - UK
      • 8.4.4.1. UK: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.4.4.2. UK: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.4.4.3. UK: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.4.5. Idiopathic Pulmonary Fibrosis Treatment Market - France
      • 8.4.5.1. France: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.4.5.2. France: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.4.5.3. France: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.4.6. Idiopathic Pulmonary Fibrosis Treatment Market - Germany
      • 8.4.6.1. Germany: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.4.6.2. Germany: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.4.6.3. Germany: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.4.7. Idiopathic Pulmonary Fibrosis Treatment Market - Italy
      • 8.4.7.1. Italy: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.4.7.2. Italy: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.4.7.3. Italy: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.4.8. Idiopathic Pulmonary Fibrosis Treatment Market - Spain
      • 8.4.8.1. Spain: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.4.8.2. Spain: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.4.8.3. Spain: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.4.9. Idiopathic Pulmonary Fibrosis Treatment Market - Netherlands
      • 8.4.9.1. Netherlands: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.4.9.2. Netherlands: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.4.9.3. Netherlands: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.4.10. Idiopathic Pulmonary Fibrosis Treatment Market - Russia
      • 8.4.10.1. Russia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.4.10.2. Russia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.4.10.3. Russia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.4.11. Idiopathic Pulmonary Fibrosis Treatment Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.4.11.2. Rest of Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.4.11.3. Rest of Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • 8.5. Idiopathic Pulmonary Fibrosis Treatment Market - Asia Pacific
    • 8.5.1. Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
    • 8.5.2. Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
    • 8.5.3. Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.5.4. Idiopathic Pulmonary Fibrosis Treatment Market - China
      • 8.5.4.1. China: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.5.4.2. China: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.5.4.3. China: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.5.5. Idiopathic Pulmonary Fibrosis Treatment Market - India
      • 8.5.5.1. India: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.5.5.2. India: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.5.5.3. India: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.5.6. Idiopathic Pulmonary Fibrosis Treatment Market - Malaysia
      • 8.5.6.1. Malaysia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.5.6.2. Malaysia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.5.6.3. Malaysia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.5.7. Idiopathic Pulmonary Fibrosis Treatment Market - Japan
      • 8.5.7.1. Japan: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.5.7.2. Japan: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.5.7.3. Japan: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.5.8. Idiopathic Pulmonary Fibrosis Treatment Market - Indonesia
      • 8.5.8.1. Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.5.8.2. Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.5.8.3. Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.5.9. Idiopathic Pulmonary Fibrosis Treatment Market - South Korea
      • 8.5.9.1. South Korea: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.5.9.2. South Korea: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.5.9.3. South Korea: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.5.10. Idiopathic Pulmonary Fibrosis Treatment Market - Australia
      • 8.5.10.1. Australia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.5.10.2. Australia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.5.10.3. Australia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.5.11. Idiopathic Pulmonary Fibrosis Treatment Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.5.11.2. Rest of Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.5.11.3. Rest of Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • 8.6. Idiopathic Pulmonary Fibrosis Treatment Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
    • 8.6.2. Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
    • 8.6.3. Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.6.4. Idiopathic Pulmonary Fibrosis Treatment Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.6.4.2. Saudi Arabia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.6.4.3. Saudi Arabia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.6.5. Idiopathic Pulmonary Fibrosis Treatment Market - UAE
      • 8.6.5.1. UAE: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.6.5.2. UAE: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.6.5.3. UAE: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.6.6. Idiopathic Pulmonary Fibrosis Treatment Market - Israel
      • 8.6.6.1. Israel: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.6.6.2. Israel: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.6.6.3. Israel: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.6.7. Idiopathic Pulmonary Fibrosis Treatment Market - South Africa
      • 8.6.7.1. South Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.6.7.2. South Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.6.7.3. South Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.6.8. Idiopathic Pulmonary Fibrosis Treatment Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.6.8.2. Rest of Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.6.8.3. Rest of Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • 8.7. Idiopathic Pulmonary Fibrosis Treatment Market - Latin America
    • 8.7.1. Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
    • 8.7.2. Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
    • 8.7.3. Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.7.4. Idiopathic Pulmonary Fibrosis Treatment Market - Mexico
      • 8.7.4.1. Mexico: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.7.4.2. Mexico: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.7.4.3. Mexico: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.7.5. Idiopathic Pulmonary Fibrosis Treatment Market - Brazil
      • 8.7.5.1. Brazil: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.7.5.2. Brazil: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.7.5.3. Brazil: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.7.6. Idiopathic Pulmonary Fibrosis Treatment Market - Argentina
      • 8.7.6.1. Argentina: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.7.6.2. Argentina: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.7.6.3. Argentina: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
    • 8.7.7. Idiopathic Pulmonary Fibrosis Treatment Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
      • 8.7.7.2. Rest of Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
      • 8.7.7.3. Rest of Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. F. Hoffmann-La Roche Ltd
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Boehringer Ingelheim International GmbH
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Bristol-Myers Squibb Company
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Medicinova, Inc
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Merck & Co., Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Galapagos NV
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Novartis AG
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Fibrogen, Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Avalyn Pharma Inc.
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Promedior, Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development

List of Tables:

  • Table 1 Global Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 2 Global Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 3 Global Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 4 North America: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 5 North America: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 6 North America: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 7 U.S.: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 8 U.S.: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 9 U.S.: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 10 Canada: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 11 Canada: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 12 Canada: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 13 Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 14 Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 15 Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 16 UK: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 17 UK: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 18 UK: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 19 France: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 20 France: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 21 France: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 22 Germany: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 23 Germany: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 24 Germany: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 25 Italy: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 26 Italy: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 27 Italy: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 28 Spain: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 29 Spain: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 30 Spain: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 31 Netherlands: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 32 Netherlands: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 33 Netherlands: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 34 Russia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 35 Russia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 36 Russia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 37 Rest of Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 38 Rest of Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 39 Rest of Europe: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 40 Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 41 Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 42 Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 43 China: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 44 China: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 45 China: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 46 India: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 47 India: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 48 India: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 49 Malaysia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 50 Malaysia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 51 Malaysia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 52 Japan: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 53 Japan: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 54 Japan: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 55 Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 56 Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 57 Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 58 South Korea: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 59 South Korea: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 60 South Korea: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 61 Australia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 62 Australia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 63 Australia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 64 Rest of Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 65 Rest of Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 66 Rest of Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 67 Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 68 Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 69 Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 70 Saudi Arabia: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 71 Saudi Arabia: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 72 Saudi Arabia: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 73 UAE: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 74 UAE: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 75 UAE: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 76 Israel: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 77 Israel: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 78 Israel: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 79 South Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 80 South Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 81 South Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 82 Rest of Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 83 Rest of Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 84 Rest of Middle East & Africa: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 85 Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 86 Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 87 Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 88 Mexico: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 89 Mexico: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 90 Mexico: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 91 Brazil: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 92 Brazil: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 93 Brazil: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 94 Argentina: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 95 Argentina: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 96 Argentina: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • Table 97 Rest of Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2020-2034 (USD billion)
  • Table 98 Rest of Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2020-2034 (USD billion)
  • Table 99 Rest of Latin America: Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2020-2034 (USD billion)
  • List of Figures:
  • Figure 1. Global Idiopathic Pulmonary Fibrosis Treatment Market, 2020-2034 (USD billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Drug Class
  • Figure 7. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class, 2024 & 2034 (USD billion)
  • Figure 8. Market by Route of Administration
  • Figure 9. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration, 2024 & 2034 (USD billion)
  • Figure 10. Market by Distribution Channel
  • Figure 11. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel, 2024 & 2034 (USD billion)
  • Figure 12. Global Idiopathic Pulmonary Fibrosis Treatment Market Assessment, By Geography, 2020-2034 (USD billion)
  • Figure 13. Strategic Analysis - Global Idiopathic Pulmonary Fibrosis Treatment Market